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Abstract
Purpose—Few treatment options are available for patients with advanced or metastatic 
hepatocellular carcinoma (HCC). Based on preclinical and early clinical efficacy signals and lack 
of overlapping toxicity, we undertook this multicenter phase II trial to estimate efficacy and safety 
of everolimus and pasireotide in advanced HCC.
Methods—Patients with advanced HCC not amenable to locoregional therapy and Child-Pugh A 
cirrhosis received everolimus 7.5 mg PO daily and pasireotide LAR 60 mg IM every 28 days. The 
primary endpoint was time to progression (TTP), with 26 events needed to evaluate if everolimus 
+ pasireotide improved TTP from 2.8 to 4.4 months, with 80% power and an alpha of 0.05. 
Secondary endpoints included response as measured by RECIST modified for HCC, treatment-
emergent adverse events, and overall survival.
Results—After 24 patients were enrolled, results of a randomized trial showing no benefit of 
everolimus in HCC were released prompting an unplanned interim analysis that found the 
conditional probability of rejecting the null hypothesis based on events in those patients was 0.08. 
Therefore accrual was halted. Patients had a median age of 59 years, 21 (88%) had BCLC stage C 
cancer, and 11 (46%) metastatic disease. Median TTP was 3.5 months (95% CI 2-5.8) and median 
survival 6.7 months (95% CI 6-infinity). Best response was stable disease in 10 patients. Grade 3 
hyperglycemia occurred in 6 (25%). There were no grade 4 treatment-emergent events.
Conclusion—Despite promising early efficacy signals, we found no benefit for the combination 
of everolimus and pasireotide in HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the second leading cause of cancer related mortality 
world-wide.[1] With an incidence that is nearly equivalent to mortality, HCC is a 
particularly deadly cancer. In part, this reflects the comorbid cirrhosis of HCC patients, but 
the high mortality rate also reflects the relative ineffectiveness of current treatment options. 
Sorafenib is the only approved drug therapy for HCC. In patients with advanced or 
metastatic HCC and compensated cirrhosis, sorafenib offers disease control in 
approximately 40% of treated patients, with time to progression of 5.5 months and median 
survival of 10.7 months, approximately 3 months longer than that of placebo treated 
patients.[2] New therapies for patients with advanced HCC are desperately needed.
Everolimus is a highly selective inhibitor of the mammalian target of rapamycin (mTOR) 
that exerts anticancer effect by directly inhibiting tumor cell growth and proliferation as well 
as by inhibiting angiogenesis via reduction in tumor HIF-1 activity, vascular endothelial 
growth factor (VEGF) production, and VEGF-induced proliferation of endothelial cells[3]. 
mTOR signaling is upregulated in a large portion of HCC cell lines, and inhibition of mTOR 
with rapamycin and everolimus has shown promising preclinical activity.[4-8] In addition to 
this robust preclinical rationale, estimates of efficacy of weekly everolimus were very 
promising in a phase I study in hepatocellular carcinoma in which disease control was seen 
in 71% of patients.[9]
Somatostatin analogs have shown to have antimitotic activity in both endocrine and non-
endocrine tumors. Octreotide, the first and most widely tested analog, showed very 
promising improvement in survival compared with supportive care in an early randomized 
trial in patients with advanced HCC.[10] Subsequent trials, however, have reported variable 
clinical activity, though the balance of evidence suggests octreotide offers little benefit for 
patients with HCC.[11-17] Variable expression of the 5 different somatostatin receptor 
subtypes on HCC cells may underlie the conflicting results and limited effect of octreotide.
[18-20] Octreotide binds only somatostatin receptor 2 with high affinity but binds with low 
affinity to receptors 3 and 5. In contrast, the novel somatostatin analog pasireotide 
(SOM230) binds with high affinity to 4 of the 5 known somatostatin receptors. As such, the 
failure to reproducibly demonstrate a benefit with approaches using somatostatin analogues 
to date may reflect an inability to appropriately hit the desired target rather than a failure of 
the approach in HCC.
Based on the preclinical rationale and lack of overlapping mechanism of action and toxicity 
of these agents, we undertook this multicenter open-label phase II trial to estimate the 
efficacy and safety of the combination of everolimus and pasireotide in advanced or 
metastatic HCC.
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This study was approved by the institutional review board at each of the participating sites 
and registered with clinicaltrials.gov (NCT01488487). All patients gave written informed 
consent prior to undergoing any study related procedures or testing.
Patients and Treatment
Patients with advanced or metastatic HCC were eligible if the diagnosis had been confirmed 
by either histopathology or a radiographic appearance characteristic of HCC (e.g. early 
arterial enhancement with subsequent venous phase washout) on MRI or multiphase CT. 
Multiple prior locoregional therapies were permitted provided there had been documented 
disease progression and the disease was no longer amenable to local approaches.
Despite being the standard first-line therapy for advanced disease, prior systemic therapy 
including sorafenib was not allowed with the exception of prior sorafenib if it was 
discontinued for intolerance, not disease progression. All patients were informed the 
standard-of -care therapeutic alternatives to this trial during the informed consent process. 
Adequate organ function was required as determined by the following criteria: Child-Pugh 
score of ≤6; INR≤1.5; bilirubin ≤1.5 times institutional upper limit of normal (IULN); AST 
or ALT ≤3 times IULN; creatinine ≤1.5 times IULN or creatinine clearance ≥50 mL/min; 
absolute neutrophil count ≥1.5 × 109/L, platelet count ≥50 × 109/L; hemoglobin ≥9 g/dL; 
Fasting serum cholesterol ≤300 mg/dL and fasting triglycerides ≤2.5 times IULN.
Treatment consisted of pasireotide LAR at 60 mg IM every 28 days and everolimus 7.5 mg 
PO on a continuous daily basis. The LAR formulation of pasireotide was chosen to optimize 
ease of use compared with twice daily injections. Everolimus adherence was evaluated by 
patient diary. Patients were evaluated prior to the start of each 28 day cycle for adverse 
events. Blood sugar was monitored at least every other day via home glucometer. Toxicity 
was graded using NCI CTCAE version 4.0. Restaging with MRI or triple-phase CT and 
alpha fetoprotein (AFP) measurements were undertaken every 8 weeks. Radiographic 
response was measured by RECIST, modified for HCC in which the target lesions are 
measured by the dimensions of enhancement on the arterial phase.[21] Treatment was 
administered continuously until disease progression, unacceptable toxicity, or withdrawal.
Statistical Considerations
The primary endpoint was time to progression (TTP), measured from time of study 
enrollment until radiographic progression. Secondary endpoints were to describe the rate of 
treatment-emergent adverse events with the everolimus/pasireotide combination, overall 
survival from enrollment, and the objective response rate (RR). To evaluate whether the 
everolimus/pasireotide combination improved TTP from the null of 2.8 to 4.4 months, 26 
events would be needed to provide 80% power with a one-sided alpha of 0.05. After 
everolimus failed to show significant single agent clinical activity in the EVOLVE-1 trial,
[22] we conducted an interim analysis in September of 2013 to evaluate the conditional 
power for demonstrating the hypothesized improvement in TTP at study completion based 
on then current data. The probability of rejecting the null hypothesis was only 0.08, 
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therefore accrual was halted. Patients were informed of these results and given the option to 
continue on treatment if deemed in their best interest by the patient and their treating 
physician. All chose to remain on treatment. Final analysis was conducted in September of 
2014 based on events through July 31st, 2014.
Results
Twenty-four patients were enrolled prior to the decision to terminate the study. Patients had 
a median age of 59 (range 23 – 87) years with a male and Caucasian predominance. 
Hepatitis C virus was present as a cause of HCC in 7 (29%) and hepatitis B virus in 2 (8%). 
Median time from diagnosis of HCC to trial enrollment was 4 months (range <1 – 88 
months). Eleven of 24 patients had undergone some prior therapy, 8 having had prior 
surgical resection, 3 had previously been determined to be intolerant to sorafenib. Patients 
were predominately BCLC C (21, 88%) but had a low median CLIP score 1.5 (interquartile 
range 1-3). Eleven (46%) patients had metastatic disease at presentation and 9 (37%) had 
portal vein involvement.
Treatment was administered for a median of two 28 day cycles (range 1-12, interquartile 
range 1-4). Only three patients required dose reduction with three treatment delays due to 
everolimus; none required dose reduction or delay of pasireotide. The most common 
treatment-emergent adverse event was hyperglycemia in 14 (58%), with 6 patients 
experiencing grade 3, 5 grade 2, and 3 patients with grade 1 hyperglycemia (Table 2). 
Alkaline phosphatase (2, 8%) and alanine aminotransferase (2, 8%) elevations were the only 
other grade 3 adverse events occurring in more than one patient. Six patients experienced a 
total of 9 serious adverse events, all of which were considered to be possibly or probably 
related to disease, not drug.
At time of analysis, all patients have been removed from protocol therapy: 15 (63%) for 
progressive disease; 6 (25%) for adverse events requiring removal per protocol; 1 due to 
death prior to radiographic evaluation though death was clinically attributed to progressive 
disease; 2 due to intolerance after 2 and 5 cycles. Median TTP was 3.5 months (95% CI 
2-5.8) months and median OS 6.7 months (95% CI 6- infinity) months (Figures 1 and 2). No 
patient experienced radiographic response according to modified RECIST. Ten of 22 
evaluable patients had stable disease as their best response.
Discussion
The combination of everolimus and pasireotide has minimal activity as first line therapy for 
patients with advanced or metastatic HCC. Four patients were maintained on study without 
progression after their second per-protocol scan at 4 months, remaining on therapy for 5, 5, 
9 and 12 cycles each. These patients were older than the average study participants (median 
age 69 versus 59) and none of them had viral hepatitis, perhaps suggesting a subgroup in 
whom future somatostatin or mTOR inhibition might be worthy of study. However, they 
also had a lower median CLIP score, hence their results may reflect a more indolent biology 
of disease and slower progression to liver failure rather than clinical benefit from the study 
therapy.
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Our finding of lack of benefit of everolimus and pasireotide is supported by recently results 
of a large randomized trial comparing everolimus to placebo in patients with HCC who had 
previously demonstrated disease progression or intolerance on first-line sorafenib.[22] 
Despite the early signal of clinical benefit for single agent everolimus in the phase I setting, 
time to progression and overall survival in everolimus-treated patients was equivalent to that 
of placebo treated patients.
Multiple pathways for which targeted therapies are available are thought to be instrumental 
in the carcinogenesis, invasion, and/or metastasis of hepatocellular carcinoma.[23] Our 
understanding of how to apply agents that target relevant pathways in HCC, however, 
remains nascent. This is not only because of the difficulty of testing multiple agents in 
patients with cirrhosis, but likely also because of marked molecular tumor heterogeneity.
[23] Multiple efforts are currently underway to more thoroughly describe the molecular and 
genetic characteristics of HCC. Incorporation of on-study biopsies of HCC patients may 
help advance this field more rapidly. Our study did include collection of correlative blood 
and tissue samples, however no analysis specific to this study has been conducted given the 
lack of efficacy of this regimen.
In conclusion, the combination of everolimus and pasireotide is ineffective as first-line 
therapy for HCC.
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Fig 1. Kaplan-Meier Estimate of Time to Progression
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Fig 2. Kaplan-Meier Estimate of Overall Survival
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Table 1
Patient Characteristics
Characteristic All Patients N=24
Age, median (range) 59 (23-87)
Sex, n (%)
  Male 16 (66%)
  Female 8 (33%)
Race, n (%)
  White 21 (88%)
  Black 1 (4%)
  Asian 2 (8%)
Latino, n(%) 0
Chronic Hepatitis C, n (%) 7 (29%)
Chronic Hepatitis B, n (%) 2 (8%)
Child-Pugh Score, median (range) 5(5-6)
Time from Diagnosis to Enrollment, Median months (range) 4(<l-88)
CLIP Score, Median (range) 1.5 (0-5)
BCLC Stagea, n (%)
  B 2 (8%)
  C 21 (88%)
Portal Vein Involvement, n (%) 9 (37%)
Extent of Cancer, n (%)
  Unifocal 2 (8%)
  Multifocal 11 (46%)
  Metastatic 11 (46%)
Prior Therapya, n (%)
  Yes 11 (46%)
  No 12 (50%)
Type of Prior Therapy (may have >1)
  TACE 4 (17%)
  TARE 2 (8%)
  Ablation 2 (8%)
  Surgery 8 (33%)
CLIP, Cancer of the Liver Italian Program; BCLC, Barcelona Clinic Liver Cancer.
a
BCLC is missing for one patient. Prior therapy is missing for one patient.
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Table 2
Frequency of Treatment-Emergent Adverse Events








Hyperglycemia 14 (58%) 3 (13%) 5 (21%) 6 (25%)
Alkaline phosphatase elevation 10 (42%) 4(17%) 4 (17%) 2 (8%)
Mucositis 9 (38%) 6 (25%) 2 (8%) 1 (4%)
Aspartate aminotransferase elevation 9 (38%) 3 (13%) 5 (21%) 1 (4%)
Fatigue 7 (29%) 5 (21%) 2 (8%) 1 (4%)
Alanine aminotransferase elevation 7 (29%) 5 (21%) 0 2 (8%)
Diarrhea 7 (29%) 3 (13%) 3 (13%) 1 (4%)
Rash 6 (25%) 5 (21%) 1 (4%) 0
Thrombocytopenia 5 (21%) 5 (21%) 0 0
Anemia 5 (21%) 4 (17%) 1 (4%) 0
Anorexia 3 (13%) 3 (13%) 0 0
Bilirubin elevation 3 (13%) 1 (4%) 2 (8%) 0
Hypertriglyceridemia 3 (13%) 3 (17%) 0 0
Nausea 3 (13%) 2 (8%) 1 (4%) 0
Neutropenia 3 (13%) 2 (8%) 1 (4%) 0
Elevated cholesterol 2 (8%) 2 (8%) 0 0
Vomiting 2 (8%) 2 (8%) 0 0
Dysgeusia 1 (4%) 1 (4%) 0 0
Edema limbs 1 (4%) 0 1 (4%) 0
Fever 1 (4%) 0 1 (4%) 0
Hypophosphatemia 1 (4%) 0 0 1 (4%)
Lymphopenia 1 (4%) 0 1 (4%) 0
Palmar-plantar erythrodysesthesia 1 (4%) 1 (4%) 0 0
Weight loss 2 (8%) 0 1 (4%) 0
Leukopenia 2 (8%) 2 (8%) 0 0
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